GO
Loading...

Enter multiple symbols separated by commas

Eli Lilly and Co

More

  • LONDON, May 26- AstraZeneca's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. AstraZeneca and Amgen have been sharing development of brodalumab since 2012 as a treatment for psoriasis, psoriatic arthritis and axial...

  • WASHINGTON— Sticky plaque gets the most attention, but now healthy seniors at risk of Alzheimer's are letting scientists peek into their brains to see if another culprit is lurking. Reisa Sperling of Boston's Brigham and Women's Hospital and Harvard Medical School, who is leading the so-called A4 study. The A4 study— it stands for Anti-Amyloid Treatment in...

  • May 15- The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson& Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization. The FDA said its Adverse Event Reporting System database...

  • U.S. FDA warns on newer class of type 2 diabetes drugs Friday, 15 May 2015 | 11:06 AM ET

    May 15- The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drug sold by AstraZeneca, Johnson& Johnson and Eli Lilly in partnership with Boehringer Ingleheim may a cause dangerously high levels of blood acids that could require hospitalization. They include AstraZeneca's Farxiga, J&J's Invokana and...

  • WASHINGTON, May 6- The U.S. Food and Drug Administration will hold a public meeting this summer to address drug company concern that restrictions on what they can say about off-label use of drugs violate their first amendment right to free speech. Efforts by drug companies to change the rules gained steam after a 2012 decision from the Second Circuit Court of...

  • Takeda to take $2.7 bln charge to settle Actos cases Tuesday, 28 Apr 2015 | 8:31 PM ET

    April 28- Takeda Pharmaceutical Co Ltd and its Takeda Pharmaceuticals U.S.A. Inc unit said on Tuesday they reached a $2.4 billion agreement to settle the majority of claims involving the diabetes drug Actos. Takeda said it will take a $2.7 billion charge against earnings to cover the settlement costs in the 2014 fiscal fourth quarter ended March 31.

  • April 23- A unit of AstraZeneca Plc has teamed up with Juno Therapeutics Inc to develop combination treatments that use the body's immune system to kill cancer cells. The partnership between AstraZeneca's research and development arm MedImmune and Juno is the latest collaboration between companies intent on developing a new class of drugs known as...

  • April 23- Eli Lilly and Co soundly beat quarterly profit estimates on lower-than-expected spending on research and marketing but stuck to its full-year earnings forecast while revenue fell but matched expectations. Lilly earned $530 million, or 50 cents per share, in the quarter, compared with $728 million, or 68 cents per share, a year earlier..

  • Early movers: PBR, MMM, CAT & more Thursday, 23 Apr 2015 | 8:12 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • The Indianapolis- based drugmaker posted a net profit of $529.5 million, or 50 cents per share, for the first quarter ended March 31, compared with a profit of $727.9 million, or 68 cents per share, a year earlier. In January, the company forecast full-year adjusted earnings of $3.10- $3.20 per share, and sales of $19.50- $20 billion. Lilly on Thursday cut its full-year...

  • Lilly profit falls 27 percent, hurt by strong dollar Thursday, 23 Apr 2015 | 6:32 AM ET

    April 23- Eli Lilly and Co reported a 27 percent fall in quarterly profit, hurt by a stronger dollar. The Indianapolis- based drugmaker posted a net profit of $529.5 million, or 50 cents per share, for the first quarter ended March 31, compared with a profit of $727.9 million, or 68 cents per share, a year earlier. Excluding items, the company earned 87 cents per share.

  • Earnings deluge could support new highs Thursday, 23 Apr 2015 | 6:05 AM ET
    An employee pre-assembles a Caterpillar engine at the Ellicott Dredges facility in Baltimore.

    Investors will eye more earnings amid the possibility of a breakout in stocks to record levels on Thursday.

  • Earnings deluge could support new index highs Wednesday, 22 Apr 2015 | 6:45 PM ET
    An employee pre-assembles a Caterpillar engine at the Ellicott Dredges facility in Baltimore.

    Investors will eye more earnings amid the possibility of a breakout in stocks to record levels on Thursday.

  • LONDON, April 22- Swiss drugmaker Roche has "renewed confidence" that drugs targeting potentially brain-destroying plaque can fight Alzheimer's disease, following promising results with a product from a rival. Pharmaceuticals head Daniel O'Day said on Wednesday Roche would look again at prospects for two of its experimental Alzheimer's drugs, both of...

  • April 20- Eli Lilly and Co said its experimental drug, ixekizumab, reduced the signs and symptoms of active psoriatic arthritis in patients more than a placebo did in a late-stage trial. Up to 30 percent of psoriasis patients develop psoriatic arthritis, an inflammatory form of arthritis that can cause swelling, stiffness and pain in and around joints, according...

  • LILLY'S PSORIATIC ARTHRITIS DRUG SUCCEEDS IN LATE-STAGE STUDY@. April 20- Eli Lilly and Co said its experimental drug, ixekizumab, was more effective than a placebo in patients with active psoriatic arthritis, in a late-stage trial. Psoriatic arthritis is a progressive and chronic disease that can cause swelling, stiffness and pain in and around joints.

  • Earnings next test for stocks after market wipeout Monday, 20 Apr 2015 | 5:52 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.

  • Earnings next test for stocks after market wipeout Friday, 17 Apr 2015 | 4:29 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.

  • LONDON, April 15- Having seen off a hostile $118 billion bid launched a year ago by U.S. rival Pfizer, Anglo-Swedish company AstraZeneca is on the move-- quite literally. Chief Executive Pascal Soriot is making AstraZeneca more nimble as hopes build for its cancer pipeline, but he still has his work cut out to keep 2015 earnings above the floor needed to protect his...

  • Why do drugs have such weird names? Friday, 10 Apr 2015 | 7:00 AM ET
    Pharmacist dispensing pills

    It can cost $75,000 to $250,000, and the names keep getting stranger as companies balance regulator concerns with the desire to market the product.